Statistics from Altmetric.com
Randomised controlled trial.
Follow up period:
Twenty five centres in six European countries, Israel, and South Africa; 2001–03.
335 children and adolescents (aged 5–17 years) with conduct disorder, oppositional defiant disorder, or disruptive behaviour disorder not otherwise specified (DSM-IV and Schedule for Affective Disorders and Schizophrenia for School-Age Children - Present and Lifetime Version criteria) who responded to 12 weeks of risperidone (0.25 to 1.5 mg/day). Exclusions: moderate or severe intellectual impairment (IQ <55); Nisonger Child Behavior Rating Form - parent version (NCBRF) conduct problem subscale score <24; schizophrenia; bipolar disorder; other serious psychological or medical conditions; use of antispychotics, lithium, anticonvulsants, or antidepressants; or with no …
For correspondence: Dr Reyes, Johnson & Johnson Pharmaceutical Research & Development, 1125 Trenton-Harbourton Road, Titusville, NJ 08530, USA;
Sources of funding: Johnson and Johnson Pharmaceutical Research and Development.
The opinions and assertions contained in this report are the private views of the author and are not to be construed as official or as reflecting the views of the National Institute of Mental Health, the National Institutes of Health, or the Department of Health and Human Services.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.